TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02955329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape tobacco leaves with nicotine out of the PAX device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will vape tobacco leaves with nicotine out of the PAX device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana leaves with nicotine out of the PAX device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Participants will vape marijuana leaves with nicotine out of the PAX device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAX Loose Leaf Vaporizer
Description: In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAX Loose Leaf Vaporizer
Description: In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAX Loose Leaf Vaporizer
Description: In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
Study: NCT03140826

Intervention type: DRUG
Intervention: meropenem
Description: Antibiotics to treat infections.
Study: NCT03171922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Diet
Description: ID group have online dietary coach every 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic Diet
Description: CD group have every 2 weeks visit at clinic
Study: NCT00268814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Description: Diacetylmorphine (i.v.), daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Description: Diacetylmorphine (i.v.), daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Description: Diacetylmorphine (i.v.), daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Description: Diacetylmorphine (i.v.), daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education and Counselling
Description: Psycho-educational group therapy and individual counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education and Counselling
Description: Psycho-educational group therapy and individual counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-education and Counselling
Description: Psycho-educational group therapy and individual counselling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education and Counselling
Description: Psycho-educational group therapy and individual counselling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone (p.o.), daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone (p.o.), daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone (p.o.), daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone (p.o.), daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management and Motivational interviewing
Description: Individual Case Management combined with Motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and Motivational interviewing
Description: Individual Case Management combined with Motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case management and Motivational interviewing
Description: Individual Case Management combined with Motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management and Motivational interviewing
Description: Individual Case Management combined with Motivational interviewing
Study: NCT02087566

Intervention type: DRUG
Group type: OTHER
Intervention: 600 mg linezolid

Intervention type: DRUG
Group type: OTHER
Intervention: 600 mg linezolid

Intervention type: DRUG
Group type: OTHER
Intervention: 600 mg linezolid
Study: NCT01610921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bronchial provocation test
Description: Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
Study: NCT04352829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIDEO-TRAINING-SESSION ABOUT MDI USE
Description: The steps were demonstrated with the brochure that illustrated correct inhalation techniques and were prepared by Turkish Respiratory Research Society-Inhalation Treatment Study Group in line with the literature and were described with a video that was designed by Turkish National Society of Allergy and Clinical Immunology (25). The video is provided with a free access on the webpage of Turkish National Society of Allergy and Clinical Immunology.The video included images that explained the steps about what to do before MDI use, how to use the device and the issues to which attention should be paid during the use of the device and focused on the skill-steps that should gradually be performed about MDI use.
Study: NCT01091129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry System (treatment with energy)
Description: Treatment with microwave energy delivery device as specified by manufacturer's instructions
Study: NCT03804151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitSpirit intervention
Description: The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
Study: NCT01307423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20mg twice daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast 20mg
Description: Apremilast 20mg twice daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30mg twice daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast 30mg
Description: Apremilast 30mg twice daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02413658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Topical use of phenytoin solution on dressings of split thickness skin graft sites.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Topical use of phenytoin solution on dressings of split thickness skin graft sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar solution
Study: NCT00942006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 100 mg bid, 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: 2g x 1 iv, 14 days
Study: NCT02696083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provant Therapy System
Study: NCT01497392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib lactate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04242537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula oxygen delivery
Description: It includes the delivery of oxygen through a high flow nasal cannula with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow nasal cannula oxygen delivery
Description: It includes the delivery of oxygen through a low flow nasal cannula coupled with head side elevation to 30 degrees to prevent desaturation and improve first pass success rate of endotracheal intubation
Study: NCT02053974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone
Study: NCT01820260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel
Study: NCT02053974

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01820260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel
Study: NCT00584974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: 0.5 mg SEP-225289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-225289
Description: 2.0 mg SEP-225289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: 150 mg Venlafaxine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT02095561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV self testing
Description: Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
Study: NCT03016611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chewing Ticagrelor LD
Description: 180 mg Chewing Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Prasugrel LD
Description: 60 mg Chewing Prasugrel
Study: NCT04687124

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil
Description: Dietary counseling including an oral nutritional supplement (ONS) containing 2.2 g of n-3 fatty acid EPA (Forticare®)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard care
Description: No specified intervention
Study: NCT04469491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled type I interferon
Description: The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WFI water nebulization
Description: The interventional arm includes a WFI water nebulization comparator.
Study: NCT02262403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and feces sampling
Description: Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood and feces sampling
Description: Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
Study: NCT04265391

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cookies
Description: Either snakehead fish cookies or standard cookies were given to subjects 75g per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cookies
Description: Either snakehead fish cookies or standard cookies were given to subjects 75g per day.
Study: NCT01967225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phosphate (Sivextro, BAY1192631)
Description: BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Study: NCT02120417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m\^2 daily given as 1000 mg/m\^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo tablets to be administered by mouth
Study: NCT03890055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Best supportive care
Study: NCT00730236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEGR-733
Description: 5-80 mg daily by mouth for 1.5 yrs
Study: NCT01962142

Intervention type: OTHER
Intervention: Assessment of activity capacities
Study: NCT04391764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone at a dose of 50 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
Study: NCT04543500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)
Description: Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)
Description: Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
Study: NCT04884828

Intervention type: DEVICE
Intervention: external gas during NIV
Description: The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
Study: NCT04304677

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: 1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES
Study: NCT03921112

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasound
Description: bedside lung ultrasound will be done for patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine tools
Description: chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
Study: NCT01098695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Family Intervention and Treatment (EcoFIT)
Description: Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
Study: NCT02986386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental occlusion restoration
Description: Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental occlusion restoration
Description: Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment of malocclusion
Description: Orthodontic therapy to treat malocclusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthodontic treatment of malocclusion
Description: Orthodontic therapy to treat malocclusion
Study: NCT06111170

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression dressing
Description: Application of dressing
Study: NCT04342559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Belamy (vaginal moisturizer)
Description: The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Belamy (vaginal moisturizer)
Description: The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period
Study: NCT00655590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 20 mg daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100 mg daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos
Study: NCT02331498

Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
Study: NCT01551498

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc Supplement
Description: Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, as mint flavored lozenges, to be taken 3 times each day
Study: NCT03194217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN-2001
Description: Bavisant dihydrochloride monohydrate for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN-2001
Description: Bavisant dihydrochloride monohydrate for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN-2001
Description: Bavisant dihydrochloride monohydrate for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04017494

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw for hematocrit and heart failure biomarkers
Description: Approximately 10 ml of blood will be drawn before administration of contrast medium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: Exhalomics
Description: Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)

Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of life questionnaire
Description: Questionnaire to be filled out by the Patient regarding quality of life perception